Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Fish and Richardson
Queensland Health
Baxter
Accenture
Covington
Healthtrust
Argus Health
Novartis
QuintilesIMS

Generated: January 19, 2018

DrugPatentWatch Database Preview

FORTEO Drug Profile

« Back to Dashboard

When do Forteo patents expire, and what generic alternatives are available?

Forteo is a drug marketed by Lilly and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and thirty-seven patent family members in thirty-seven countries.

The generic ingredient in FORTEO is teriparatide recombinant human. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the teriparatide recombinant human profile page.
Summary for FORTEO
International Patents:137
US Patents:7
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 65
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:FORTEO at DailyMed
Drug patent expirations by year for FORTEO
Pharmacology for FORTEO

US Patents and Regulatory Information for FORTEO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-001 Nov 26, 2002 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-001 Nov 26, 2002 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-001 Nov 26, 2002 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for FORTEO
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Injection 250 mcg/mL, 2.4 mL prefilled Pen ➤ Subscribe 7/27/2015

Non-Orange Book US Patents for FORTEO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,857,791 Medication dispensing apparatus with gear set having drive member accommodating opening ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for FORTEO

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Covington
Queensland Health
Daiichi Sankyo
Mallinckrodt
Fish and Richardson
AstraZeneca
Baxter
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot